Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson’s Disease in the United States

ABSTRACT: In 2015, the US Food and Drug Administration approved levodopa-carbidopa intestinal gel (LCIG; also known as carbidopa-levodopa enteral suspension in the US) for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. LCIG provides a continuous infusion of levodo...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Adv Ther
Päätekijät: Amjad, Fahd, Bhatti, Danish, Davis, Thomas L., Oguh, Odinachi, Pahwa, Rajesh, Kukreja, Pavnit, Zamudio, Jorge, Metman, Leonard Verhagen
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Healthcare 2019
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6822848/
https://ncbi.nlm.nih.gov/pubmed/31278691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-01014-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia